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Abstract
Background: Currently, no vaccine against Pseudomonas is available. IC43 is a new, recombinant, protein (OprF/I)-based
vaccine against the opportunistic pathogen, Pseudomonas aeruginosa, a major cause of serious hospital-acquired
infections. IC43 has proven immunogenicity and tolerability in healthy volunteers, patients with burns,
and patients with chronic lung diseases. In order to assess the immunogenicity and safety of IC43 in patients who are
most at risk of acquiring Pseudomonas infections, it was evaluated in mechanically ventilated ICU patients.
Methods: We conducted a randomized, placebo-controlled, partially blinded study in mechanically ventilated
ICU patients. The immunogenicity of IC43 at day 14 was determined as the primary endpoint, and safety, efficacy
against P. aeruginosa infections, and all-cause mortality were evaluated as secondary endpoints. Vaccinations
(100 μg or 200 μg IC43 with adjuvant, or 100 μg IC43 without adjuvant, or placebo) were given twice in a 7-day
interval and patients were followed up for 90 days.
Results: Higher OprF/I IgG antibody titers were seen at day 14 for all IC43 groups versus placebo (P < 0.0001).
Seroconversion (≥4-fold increase in OprF/I IgG titer from days 0 to 14) was highest with 100 μg IC43 without
adjuvant (80.6%). There were no significant differences in P. aeruginosa infection rates, with a low rate of invasive
infections (pneumonia or bacteremia) in the IC43 groups (11.2-14.0%). Serious adverse events (SAEs) considered
possibly related to therapy were reported by 2 patients (1.9%) in the group of 100 µg IC43 with adjuvant. Both
SAEs resolved and no deaths were related to study treatment. Local tolerability symptoms were mild and rare
(<5% of patients), a low rate of treatment-related treatment-emergent adverse events (3.1–10.6%) was observed
in the IC43 groups.
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Conclusion: This phase II study has shown that IC43 vaccination of ventilated ICU patients produced a significant
immunogenic effect. P. aeruginosa infection rates did not differ significantly between groups. In the absence of
any difference in immune response following administration of 100 μg IC43 without adjuvant compared with
200 μg IC43 with adjuvant, the 100 μg dose without adjuvant was considered for further testing of its possible
benefit of improved outcomes. There were no safety or mortality concerns.
Trial registration: ClinicalTrials.gov, NCT00876252. Registered on 3 April 2009.
Keywords: Pseudomonas aeruginosa, Vaccination, Immunity, Immunocompromised host, Bacterial infections, Mortality
Background
The opportunistic bacterial pathogen Pseudomonas
aeruginosa is a major cause of serious hospital-acquired
infections [1]. P. aeruginosa is a particular problem for
seriously ill patients in intensive care units (ICUs), with
important associated infections being ventilator-associated
pneumonia, catheter-related bloodstream infections, and
catheter-associated urinary tract infections [2–4]. The risk
of Pseudomonas infections increases with duration of ICU
stay, and infection is associated with an increased risk of
mortality [5].
Effective treatment of P. aeruginosa infection is hin-
dered by the organism’s ability to develop resistance to
antibacterial agents, even during the course of treatment
against the infection [2, 6]. The escalating prevalence of
antibiotic resistance in P. aeruginosa requires develop-
ment of new strategies. Vaccine research has included
approaches to generating antibodies to surface mole-
cules, such as lipopolysaccharide and outer membrane
proteins [7], and a role for T-helper type 17 (Th17)-
stimulating protein antigens has been proposed [8].
However, there is currently no vaccine available for P.
aeruginosa.
Vaccines that are based on outer membrane proteins
are attractive candidates because outer membrane pro-
teins are conserved among all the 17 known serotypes of
P. aeruginosa, and are still present after phenotypic
conversion of P. aeruginosa [9]. IC43 (Valneva, Vienna,
Austria) is a recombinant outer membrane protein
(Opr)-based vaccine against P. aeruginosa, consisting of
epitopes of OprF and OprI. It has shown promising
results in healthy volunteers, patients with burns, and
patients with chronic lung disease [10–15], with proven
immunogenicity at individual doses of 500–1000 μg via
intranasal application, and 20–500 μg via intramuscular
injection. Confirmation of the optimal dose in the target
population of patients at particularly high risk of acquir-
ing P. aeruginosa infections, such as ICU patients, is
now required.
We present herein the results of a dose-finding study
of IC43 in ventilated ICU patients. The primary object-
ive was to assess the immunogenicity of IC43 at doses of
100 μg and 200 μg with adjuvant, respectively, or 100 μg
without adjuvant, 14 days after the first vaccination.
Secondary objectives were to investigate immunogenicity
up to day 90, safety and tolerability, to estimate the rate
of P. aeruginosa infections, and to analyze the impact of
IC43 vaccination on other factors, including overall
survival. None of the results of this study have been pre-
viously reported.
Methods
Additional detail on the methods is provided in
Additional file 1.
Trial design
This was a phase II, randomized, placebo-controlled,
partially blinded, parallel-group, multicenter study to
assess the immunogenicity and safety of IC43 vaccin-
ation in mechanically ventilated ICU patients. Doses of
100 μg and 200 μg with adjuvant and a dose of 100 μg
without adjuvant were tested. Patients were enrolled,
randomized and vaccinated on day 0. A second vaccin-
ation was given on day 7. Clinical study visits were
performed up to day 90 (Fig. 1).
Subjects were initially randomized in a 1-1-1 ratio to
IC43 100 μg, IC43 200 μg, or placebo (with both IC43
doses given with aluminum hydroxide adjuvant). After
137 patients had been enrolled, data became available
from a phase-I trial, in which both 100 μg IC43 without
adjuvant and 100 μg IC43 with adjuvant had a favorable
safety profile and a similar immunogenicity profile. Based
on the newly available data and following the recommen-
dation of a Data Safety Monitoring Board (DSMB), a
protocol amendment was introduced to add a fourth
treatment group in this phase II study, to assess IC43
100 μg without aluminum hydroxide adjuvant. From this
point in the study, randomization was performed in a
2:1:1:1 ratio (double the number of patients randomized
to 100 μg IC43 without adjuvant to achieve equal num-
bers per group).
The randomization lists were generated by a statistician
at a contract research organization (Assign Data Manage-
ment and Biostatistics GmbH, Innsbruck, Austria), using
nQuery Advisor. A hard copy and the electronic files were
stored in a bank deposit until the study was un-blinded.
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The first randomization code had a block size of 3
(1 × IC43 100 μg, 1 × IC43 200 μg, and 1 × placebo).
After the protocol amendment and introduction of the
fourth treatment group, the code had a block size of 5
(1 × IC43 100 μg, 1 × IC43 200 μg, 2 × IC43 100 μg with-
out adjuvant, and 1 × placebo). The randomization was
stratified by study center. Each subject was assigned the
next free medication kit (randomization) number for the
corresponding study center in ascending order.
A blinded independent Clinical Endpoint Committee
(CEC) reviewed and confirmed diagnosis of P. aeruginosa
infections. A blinded independent DSMB evaluated safety
data and provided recommendations to the sponsor.
Study population
The main inclusion criteria were: male or females, 18–80
years of age; ICU patients on mechanical ventilation with
an expected need of continued mechanical ventilation for
>48 hours after inclusion (study inclusion had to occur as
soon as possible after start of mechanical ventilation); a
high probability of survival for ≥48 hours; and written in-
formed consent (e.g. by the patient or legal representative)
or waiver according to national regulations.
Patients were excluded if they had low severity of illness
(i.e. acute physiology score <8 at visit 0; 12 physiological
values, clinically worst value was recorded, higher scores
indicate more severe illness), were <6 months post-organ
transplantation, had severe thrombocytopenia or other
coagulopathy making them unsuitable for intramuscular
injection, had expected plasmapheresis or immune-
adsorption during the study period, had used any other
investigational or non-registered drug (except the study
vaccine) within 30 days prior to IC43 vaccination at day 0,
were pregnant or lactating, or had been committed invol-
untarily to an institution.
The study was performed at 34 sites, mainly public
hospitals or university hospitals, in Europe (Austria,
Romania, Belgium, Hungary, Spain, and Turkey) and
South America (Argentina and Chile).
Study vaccine
The IC43 vaccine (Met-Ala-(His)6-OprF190–342-OprI21–83)
consists of the C-terminal part of OprF and the entire
outer membrane protein OprI with six histidine residues
fused to the N-terminus of the recombinant protein
(OprF/I). IC43 was produced in Escherichia coli. The puri-
fied protein was stored in phosphate-buffered saline (PBS)
solution and diluted in 0.9% sodium chloride. The protein
was absorbed to aluminum hydroxide as adjuvant (400 μg
protein per ml aluminum hydroxide) or directly filled in
glass vials. The final protein concentration was 100 μg/ml.
The placebo was PBS solution containing 0.9% sodium
chloride and 400 μg aluminum hydroxide.
The drug substance (purified OprF/I fusion protein)
was manufactured by Eurogentec S.A. Biologics, Liege
Science Park-4102, Seraing, Belgium. The IC43 drug
product and placebo for injection were produced by
SynCo Biopartners B.V., Paasheuvelweg 30, 1105BJ
Amsterdam ZO, The Netherlands. All study drugs were
produced and released in accordance with Good Manu-
facturing Practice.









Immunogenicity X X X X X X
Safety / tolerability X X X X X X
Infection assessment 
†
X X X X X X
Fig. 1 Study design. *Day 0 assessments were in the intensive care unit (ICU). Subsequent visits were performed in the ICU, hospital, or outpatient
setting. Key study visits were at days 0, 7, 14, and 90, and ICU discharge. Optional study visits were performed on days 28, 42, 56, and 70, and only if
the patient was still in the ICU or hospital. The total number of visits was dependent on the length of hospital stay (maximum 9 visits). The day-90 visit
was considered essential; if patients were not able to attend in person, a telephone call for safety assessment was conducted. The primary endpoint
(immunogenicity assessment) was outer membrane protein (OprF/I)-specific immunoglobulin G (IgG) antibody titer at day 14. †Surveillance cultures
for Pseudomonas aeruginosa (P. aeruginosa) diagnosis were taken from blood, wounds (if applicable), respiratory tract, urine, and central venous catheter
at visits conducted in the ICU. In between these visits, and at other visits up to day 90, cultures for P. aeruginosa diagnosis were taken at the investigator’s
discretion, if medically indicated
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IC43 with adjuvant and placebo were stored in refrig-
erators at 2–8 °C. IC43 without adjuvant was delivered
on dry ice and stored in freezers at −20 °C (+/− 5 °C).
IC43 with adjuvant and placebo vials were shaken before
use. Vials containing IC43 without adjuvant were thawed
for 40 minutes at room temperature, reversed 10 times
before use, and administered within 30 minutes.
IC43 without adjuvant (i.e. purified OprF/I fusion
protein) was administered un-blinded, and IC43 with ad-
juvant and placebo were administered blinded because of
different appearance and storage conditions. Intramuscu-
lar injections were given in the deltoid region of the upper
arm. Sealed envelopes containing details of treatment allo-
cation (one per patient) were provided to study sites in
case emergency un-blinding was required.
Outcomes
The primary endpoint was immunogenicity at day 14,
determined by OprF/I-specific immunoglobulin G (IgG)
antibody titer. Subgroup analyses were performed for
immunosuppression, gender and age. Secondary endpoints
included OprF/I-specific IgG antibody titers on days 7, 28,
42, 56, 70, and 90, CEC-confirmed P. aeruginosa infections
up to day 90, and overall survival, safety, and tolerability.
Immunogenicity, efficacy, safety, and tolerability
measures
Serum was collected for immunogenicity assessments
(OprF/I ELISA) on days 0, 7, 14, 28, 42, 56, 70, 90, and
ICU discharge. P. aeruginosa surveillance cultures were
taken at each ICU study visit. Bacteremia was assessed
by bacterial blood culture. Data from respiratory cultures
and urine measurements were analyzed quantitatively and
data from wounds were analyzed qualitatively. Semi-
quantitative microbiological culture of central venous
catheter samples was performed if possible, otherwise
qualitative analysis was performed. In addition, cultures
were collected at other times (i.e. between visits), at the
investigator’s discretion, during the ICU and hospital
stay.
The sequential organ failure assessment (SOFA) score
(range 0–24, with scores for each organ system (respiratory,
coagulation, liver, cardiovascular, central nervous system,
and kidney) ranging from 0 (normal) to 4 (most abnormal))
was recorded at each visit during the ICU stay.
Adverse events (AEs) and serious adverse events (SAEs),
clinical laboratory tests (hematology, clinical chemistry
and urinalysis), and local tolerability and systemic toler-
ability assessments were performed at each visit. Local
tolerability (i.e. reactions at the injection site) was eval-
uated by the investigator for up to 1 hour after each
vaccination. At each visit, the injection site was also
inspected and evaluated by the investigator. Grading was
performed according to Food and Drug Administration
Guidance for Industry [16], modified to reflect the guid-
ance of the Brighton Collaboration. For each type of local
reaction (erythema/redness, induration, pain, swelling,
itching, or tenderness), a record was made of whether it
was present and, if present the severity was graded as <1,
mild (grade 1), moderate (grade 2), severe (grade 3) or
potentially life threatening (grade 4).
For visits performed at the ICU, systemic tolerability
of the vaccination was assessed by monitoring vital signs
(pulse and blood pressure). Vital signs were monitored
over a period of 1 hour after vaccination. If the second
vaccination was performed at the hospital ward or in the
outpatient setting, patients were observed by the investi-
gator for 1 hour after vaccination for the assessment of
local and systemic tolerability and for immediate treat-
ment of possible side effects.
Adverse events were coded according to the Medical
Dictionary for Regulatory Activities (MedDRA) coding
dictionary version 11.1. Treatment-emergent adverse events
(TEAEs) were defined as those events for which the first
onset or worsening was simultaneous with or after the first
vaccination.
Sample size
A total of 400 patients (100/group) was required to pro-
vide power of 80% for the detection of a pairwise differ-
ence between the study groups in immunogenicity
(primary study endpoint, day 14) (t test for independent
comparisons), based on OprF/I-specific antibody titer
data from a phase I study.
The sample size allowed for the estimation of an
expected P. aeruginosa infection rate of 7% with a precision
of +/− 5.0% (two-sided 95% confidence interval (CI)). This
study was not powered to detect differences in P. aerugi-
nosa infections between treatment groups. The intention
for collecting P. aeruginosa infections was to investigate the
epidemiology to prepare for an adequately powered phase
III study.
Statistical methods
Statistical analyses were performed using SAS® version
9.2 (SAS Institute, Cary, NC, USA). Primary immuno-
genicity analysis compared the OprF/I-specific IgG anti-
body geometric mean titer (GMT) on day 14 among the
four treatment groups using the intention-to-treat (ITT)
population. GMTs and GMT ratios were estimated by
applying analysis of variance including pooled site and
group as factors, using log 10-transformed data and
taking the anti-log of the resulting point estimates for
the least squares means, pair-wise least squares means
differences and the corresponding 95% confidence inter-
vals (CIs). Tukey’s honestly significant difference test was
applied for pairwise comparisons. Similar analysis of
OprF/I IgG titers was performed for other time points in
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the study (secondary analysis) and in subgroups based on
immunosuppressive status, gender, and age.
Seroconversion, P. aeruginosa infections, mortality, and
SOFA score analyses
The number and percentage of patients with seroconver-
sion (at least fourfold increase in OprF/I-specific IgG
antibody titers from days 0 to 14) were summarized with
95% CIs calculated according to Wilson’s method, as
recommended by Altman [17]. The number and percent-
age of patients with CEC-confirmed P. aeruginosa infec-
tions by event type was calculated (overall and by time of
onset: baseline (day 0), up to day 7, between days 7 and
14, and between days 14 and 90). The Fisher-Freeman-
Halton test was used to test for a difference among the
treatment groups for each event type.
A Kaplan-Meier survival curve was calculated by treat-
ment group to show time until death from the date of
first vaccination (day 0). The post-hoc log-rank test and
Cox regression analysis (with group as a factor) was used
to compare mortality rates between the treatment
groups at day 28. Additional post-hoc Cox regression
analysis (with group as a factor) was applied to analyze
time until death. Post-hoc Cox regression analysis was
used to examine correlation between the OprF/I-specific
IgG antibody titer and the overall mortality rate, using
log-transformed values. Descriptive statistics were pro-
vided for the SOFA score.
Safety and tolerability analyses
Descriptive statistics were used to summarize safety and
tolerability data. For TEAEs, the Fisher-Freeman-Halton
test was used to test for a difference among the treat-
ment groups.
Analysis populations
The ITT analysis population was defined as all randomized
patients who received at least one vaccination. Patients
were analyzed according to the treatment group to which
they were randomized, rather than by the actual treatment
received. Primary immunogenicity and efficacy analyses
were based on the ITT population.
The safety population was defined as all patients who
received at least one vaccination using the actual treat-
ment received. The safety population was used for safety
and tolerability analyses, demographic, and baseline data.
The safety population and ITT population were identical.
Fig. 2 Patient disposition. *Dosage deviations were reported in 9 (2.5%), 11 (3.0%), 12 (3.2%), and 16 (4.5%) patients, in the IC43 100 μg with adjuvant,
100 μg without adjuvant, 200 μg with adjuvant, and placebo groups, respectively. Treatment assignment deviations were reported in 2 (0.6%), 5 (1.4%), 3
(0.8%), and 2 (0.6%) patients, respectively. †Early study terminations due to patient deaths, as documented in the case report form. In addition, a further
patient from the group randomized to IC43 100 μg without adjuvant who died, and for whom the date and primary cause of death was missing, is not
included in this figure. f/up follow up, ITT intention-to-treat, W/d withdrawn, w/o adj without aluminum hydroxide adjuvant, with adj with aluminum
hydroxide adjuvant
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The per-protocol (PP) population was defined as all ran-
domized patients who received both vaccinations, excluding
those subjects with at least one major protocol deviation. PP
population analysis was considered supportive.
Results
Study participation
The study was conducted between January 2009 and
February 2010. Patient disposition is illustrated in Fig. 2.
The groups were similar in terms of demographic and
baseline characteristics (Table 1), reasons for ICU admis-
sion (Table 2), and the duration of ventilation, and ICU
and hospital stay (Table 3). There were no major differ-
ences in the use of concomitant immunosuppressive
agents, non-steroidal anti-inflammatory drugs, or anti-
infective agents. In particular, there were no differences
between the treatment groups in the numbers of patients
receiving P. aeruginosa-relevant antibiotics (Table 4).
Immunogenicity data
OprF/I-specific IgG antibody titers are illustrated for
each study visit in Fig. 3. For the primary endpoint,
OprF/I-specific IgG antibody titer on day 14, there was a
statistically significant overall treatment effect (P < 0.0001;
ITT population). On pairwise comparisons there were sta-
tistically significantly higher titers in each of the three
IC43 treatment groups on day 14, compared with placebo
(all P < 0.0001), thus demonstrating the presence of an im-
mune response following vaccination with both IC43
doses and formulations. There was no difference in im-
mune response on day 14 following the 100 μg dose with
or without adjuvant (P = 0.0735). However, there was a
statistically significant difference between the doses of
100 μg and 200 μg with adjuvant (P = 0.0344), with a
greater immune response to the higher dose, indicating a
dose-response relationship in the groups randomized to
IC43 with adjuvant. However, on day 14 the 200 μg dose
with adjuvant was not more immunogenic than the
100 μg dose without adjuvant (P = 0.9933).
In the subgroup analyses of OprF/I-specific IgG anti-
body titer on day 14 by immunosuppressive status, a sta-
tistically significant overall treatment effect was detected
in patients with high and with low immunosuppression
(P = 0.0001 and P = 0.0429, respectively), showing that
Table 1 Baseline demographic and clinical characteristics (ITT population)
Parametera IC43 100 μg with adj
N = 104
IC43 100 μg w/o adj
N = 98






Age (years) 57.0 (16.2) 54.3 (15.3) 55.2 (15.7) 58.1 (15.3) 56.1 (15.6)
Weight (kg) 82.0 (19.2) 84.6 (17.6) 82.5 (17.9) 82.5 (21.7) 82.9 (19.1)
Height (cm) 170.8 (10.5) 173.5 (9.1) 171.5 (8.2) 171.5 (10.0) 171.8 (9.5)
Sex
Male 64 (61.5) 70 (71.4) 72 (71.3) 61 (62.2) 267 (66.6)
Female 40 (38.5) 28 (28.6) 29 (28.7) 37 (37.8) 134 (33.4)
Race
Caucasian 95 (91.3) 93 (94.9) 94 93.1) 92 (93.9) 374 (93.3)
Asian 2 (1.9) 1 (1.0) 0 (0.0) 2 (2.0) 5 (1.2)
Black 1 (1.0) 0 (0.0) 2 (2.0) 1 (1.0) 4 (1.0)
Other 6 (5.8) 4 (4.1) 5 (5.0) 3 (3.1) 18 (4.5)
HIV status
Positive 0 (0.0) 2 (2.0) 0 (0.0) 0 (0.0) 2 (0.5)
Missing 2 (1.9) 1 (1.0) 3 (3.0) 3 (3.1) 9 (2.2)
aData are presented as mean (standard deviation) for age, weight and height, and number (%) of patients for sex, race, and HIV status. HIV human immunodeficiency
virus, ITT intention-to-treat, w/o adj without aluminum hydroxide adjuvant, with adj with aluminum hydroxide adjuvant
Table 2 Reasons for first admission to intensive care unit (ITT population)
Reason for first admissiona IC43 100 μg with adj
(N = 104) Number (%)
IC43 100 μg w/o adj
(N = 98) Number (%)
IC43 200 μg with adj
(N = 101) Number (%)
Placebo (N = 98)
Number (%)
Total (N = 401)
Number (%)
Medicalb 82 (78.8) 75 (76.5) 80 (79.2) 74 (75.5) 311 (77.6)
Surgical 8 (7.7) 4 (4.1) 9 (8.9) 11 (11.2) 32 (8.0)
Traumatic 14 (13.5) 19 (19.4) 12 (11.9) 12 (12.2) 57 (14.2)
Unclassifiable 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.0) 1 (0.2)
aPatients may have been admitted more than once; only the first admission is classified. bIncludes cardiopulmonary resuscitation, stroke, sepsis, respiratory
insufficiency, and cardiac arrest. ITT intention-to-treat; w/o adj without aluminum hydroxide adjuvant, with adj with aluminum hydroxide adjuvant
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the immune response was present irrespective of im-
munosuppressive status. Similarly, significant treatment
effects were noted on day 14 in both gender subgroups
(i.e. male and female patients) and both age subgroups
(<65 and ≥65 years) (all P < 0.0001), indicating that the
immune response following IC43 vaccination was present
in both genders and age groups. Pairwise comparisons
showed the OprF/I-specific IgG antibody titer on day 14
was significantly higher in the group randomized to
200 μg with adjuvant compared with group randomized
to 100 μg with adjuvant among male patients and in pa-
tients aged <65 years (P = 0.0319 and P = 0.0142, respect-
ively), reflecting the dose-response relationship for the
groups receiving IC43 with adjuvant, which was observed
in the ITT population. However, the 200 μg dose with
adjuvant was not more immunogenic than the 100 μg
dose without adjuvant in these subgroups, also reflecting
the overall ITT population.
Seroconversion (≥4-fold increase in OprF/I-specific IgG
antibody titer from days 0 to 14) was observed in ≥65.0%
of patients in the IC43 treatment groups and 7.0% of
patients in the placebo group (Table 5). Seroconversion
was highest in the group receiving 100 μg IC43 without
adjuvant (80.6%).
P. aeruginosa infection rates
Data from patients with any P. aeruginosa-positive cul-
ture result were evaluated by the CEC. In total, results
from 148 patients were reviewed by the CEC, with a
similar percentage of patients in each treatment group:
39 (37.5%), 37 (37.8%), 40 (39.6%), and 32 (32.7%) pa-
tients in the groups randomized to 100 μg with adjuvant,
100 μg without adjuvant, 200 μg with adjuvant, or
placebo, respectively (ITT population).
Invasive infections (pneumonia or bacteremia) were
reported by 11.2–14.0% of patients in the IC43 groups
and 6.1% subjects in the placebo group (Table 6). Diffe-
rences in the P. aeruginosa infection types were not
statistically significantly different between treatment
groups; hence, no conclusion can be drawn on a treat-
ment effect.
Mortality
Survival curves are shown in Fig. 4. By day 28, the number
(percentage) of patients who had died was 26 (26.8%), 20
(21.7%), 25 (26.0%) and 36 (40.0%) in the groups random-
ized to 100 μg IC43 with adjuvant, 100 μg IC43 without
adjuvant, 200 μg IC43 with adjuvant, and placebo, respect-
ively (safety population). Corresponding data for overall
(study end) mortality were 37 (35.6%), 28 (28.6%), 38
(37.6%), and 42 (42.9%) patients, respectively.
There were no major differences among the treatment
groups in terms of mean (and median) SOFA score on day
0 (baseline). The median baseline SOFA score was highest
in the placebo group (9.0 versus 8.0 in each of the IC43
groups) (Table 7). However, by day 14 the median SOFA
score was lowest in the placebo group (4.0 versus 5.0, 5.5,
and 6.0 with the IC43 100 μg dose with adjuvant, the IC43
100 μg dose without adjuvant, and the IC43 200 μg dose
with adjuvant, respectively), even though mortality ap-
peared to be higher in the placebo group than in the IC43
groups from day 14 onward (Fig. 4).
Although there was some variance in the mortality per
study center, a cox regression analysis showed that on a
treatment level, the observed effect between the groups
randomized to 100 μg IC43 without adjuvant or to
placebo remained significant (P = 0.0079).
Safety and tolerability
The proportion of patients who experienced at least one
TEAE was similar across the treatment groups (95 (91.3%),
Table 3 Duration of ventilation, intensive care unit stay, and hospital stay (safety population)
Duration (days)a IC43 100 μg with adj
(N = 104)
IC43 100 μg w/o adj
(N = 98)






Ventilation 18.5 (13.4) 18.7 (18.6) 18.5 (17.2) 17.9 (14.8) 18.4 (16.0)
ICU stay 26.6 (17.7) 24.3 (17.8) 24.0 (16.9) 23.5 (16.0) 24.6 (17.1)
Hospital stayb 15.2 (20.3) 13.9 (14.6) 14.4 (20.9) 12.4 (17.6) 14.0 (18.5)
aData are presented as mean (standard deviation); includes non-censored data only. Data were either censored or missing for 14 patients (ventilation), 11 patients
(ICU stay) and 32 patients (hospital stay). bNot including ICU stay. ICU intensive care unit, w/o adj without aluminum hydroxide adjuvant, with adj with aluminum
hydroxide adjuvant
Table 4 Number of patients receiving P. aeruginosa relevant antibiotics (ITT population)
IC43 100 µg with adj
(N = 104) No. (%)
IC43 100 µg w/o adj
(N = 98) No. (%)
IC43 200 µg with adj
(N = 101) No. (%)
Placebo
(N = 98) No. (%)
Total
(N = 401) No. (%)
Subjects with at least one P. aeruginosa
relevant antibiotics during the study
84 (80.8) 76 (77.6) 84 (83.2) 83 (84.7) 327 (81.5)
ITT intention-to-treat; w/o adj without aluminium hydroxide adjuvant; with adj with aluminium hydroxide adjuvant
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83 (84.7%), 87 (86.1%) and 87 (88.8%) patients in the groups
randomized to 100 μg IC43 with adjuvant, 100 μg without
adjuvant, 200 μg with adjuvant, or placebo, respectively
(safety population)) with no statistically significant differ-
ence among groups (P > 0.05, Fisher-Freeman-Halton test).
The percentage of patients who had at least one treatment-
related TEAE was small (3.1 − 10.6% in the IC43 groups,
and 6.1% in the placebo group), with no statistically sig-
nificant difference among the groups (P > 0.05, Fisher-
Freeman-Halton test). Overall, the number and nature of
treatment-related TEAEs did not point to any safety
concern.
SAEs were reported by 59 (56.7%), 38 (38.8%), 52
(51.5%), and 53 (54.1%) patients in the groups random-
ized to 100 μg IC43 with adjuvant, 100 μg without adju-
vant, 200 μg with adjuvant, or placebo, respectively, with
no statistically significant difference among the groups
(P > 0.05, Fisher-Freeman-Halton test). None of the
deaths was considered by the investigator to be related
to study treatment. SAEs (pulmonary hemorrhage and
shock) that were considered to be possibly related to
treatment were reported by 2 (1.9%) patients in the
group receiving 100 μg IC43 with adjuvant. These two
events were also the only cases of related severe events.
Both SAEs resolved. Local tolerability symptoms, such
as erythema, pain, tenderness (if assessable in sedated or
unconscious patients) were mild and rare (<5% of
patients). Evaluation of laboratory parameters did not
indicate any safety issues.
Discussion
This phase II study investigated two doses and two for-
mulations of a P. aeruginosa vaccine in ventilated ICU
patients for immunogenicity as the primary study end-
point, and for safety and efficacy as secondary outcomes.
Both doses of IC43 (100 μg and 200 μg) were effective at
producing an immune response by day 14 (7 days after
the second vaccination), as measured by OprF/I-specific
IgG antibody titer, and the immunogenic effect persisted
until day 70.
The IC43 vaccine entails a 6xHis-tag; however, in gen-
eral there were no objections from the regulators against
the use of the His-tagged protein. The vaccine has been
Fig. 3 Outer membrane protein F/I hybrid vaccine (OprF/I)-specific IgG antibody geometric mean titers (GMT) (U/ml) (intention-to-treat (ITT)
population). Note, on day 14 (primary endpoint), there was a statistically significant difference in the OprF/I-specific IgG antibody titer in all IC43
groups compared with placebo (all P < 0.0001). In addition, there were statistically significant differences between all IC43 groups versus placebo
on days 28, 42, 56, and 70 (P ≤ 0.0119). At baseline (day 0), 25 subjects had a detectable OprF/I IgG titer >350 U/ml; none of these patients had a
baseline infection. *Statistically significant difference between 200 μg and 100 μg IC43 with adjuvant (P = 0.0344). †Two outliers representing
measurements in six subjects (11,582 and 7,935 U/ml). ‡Optional visit. w/o without aluminum hydroxide adjuvant, ANOVA analysis of variance
Table 5 Seroconversion rates from days 0 to 14 (ITT population)
Treatment group Patients seroconverted by day 14a n (N) Percentage 95% Confidence intervalb
IC43 100 μg with adj 52 (80) 65.0% (54.1%, 74.5%)
IC43 100 μg w/o adj 58 (72) 80.6% (70.0%, 88.0%)
IC43 200 μg with adj 54 (72) 75.0% (63.9%, 83.6%)
Placebo 5 (71) 7.0% (3.0%, 15.4%)
aSeroconversion defined as ≥4-fold increase in Outer membrane protein F/I hybrid vaccine (OprF/I)-specific IgG antibody titer from days 0 to 14. b95% Confidence
interval calculated according to Wilson’s method, as recommended by Altman [17]. ITT intention-to-treat, n number of patients seroconverted, N number of
patients with data, w/o adj without aluminum hydroxide adjuvant, with adj with aluminum hydroxide adjuvant
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applied in two clinical studies, including the present one
and there were no safety concerns observed. Hence
there is currently no indication that the 6xHis-tagged
IC43 vaccine would induce any adverse events due to
the His-tag.
The addition of aluminum hydroxide adjuvant to IC43
did not appear to improve immunogenicity. The obser-
vation that the antigen is as immunogenic without adju-
vant as it is with adjuvant is surprising, but has been
seen in a previous study with IC43 in healthy volunteers
Table 6 Confirmed P. aeruginosa infections up to day 90 (overall and stratified by time period for first time of onset) (ITT population)
Culture typea Time period IC43 100 μg with adj IC43 100 μg w/o adj IC43 200 μg with adj Placebo Overall
N = 104 N = 98 N = 101 N = 98 P valueb
n (%) N’ n (%) N’ n (%) N’ n (%) N’
Invasive Overall 14 (13.5) 104 11 (11.2) 98 14 (14.0) 100 6 (6.1) 98 0.2533
infectionc Day 0 (baseline) 3 (2.9) 104 0 (0.0) 98 4 (4.0) 100 0 (0.0) 98
Days 0 to ≤7d 7 (6.7) 104 5 (5.1) 98 9 (9.0) 100 4 (4.1) 98
>Days 7 to ≤14 2 (2.1) 97 2 (2.2) 89 4 (4.4) 90 1 (1.3) 79
>Days 14 ≤ 90 5 (6.0) 84 4 (4.9) 81 1 (1.3) 79 1 (1.4) 74
Bacteremia Overall 10 (9.6) 104 7 (7.1) 98 9 (8.9) 101 6 (6.1) 98 0.7943
Day 0 (baseline) 1 (1.0) 104 0 (0.0) 98 1 (1.0) 101 0 (0.0) 98
Days 0 to ≤7d 4 (3.8) 104 5 (5.1) 98 5 (5.0) 101 4 (4.1) 98
>Days 7 to ≤14 1 (1.0) 97 1 (1.1) 89 3 (3.3) 91 1 (1.3) 79
>Days 14 ≤ 90 5 (6.0) 84 1 (1.2) 81 1 (1.3) 80 1 (1.4) 74
Pneumonia Overall 5 (4.8) 104 4 (4.1) 98 6 (6.0) 100 0 (0.0) 98 0.0693
Day 0 (baseline) 2 (2.0) 104 0 (0.0) 98 4 (4.0) 100 0 (0.0) 98
Days 0 to ≤7d 4 (3.8) 104 0 (0.0) 98 5 (5.0) 100 0 (0.0) 98
>Days 7 to ≤14 1 (1.0) 97 1 (1.1) 89 1 (1.1) 90 0 (0.0) 79
>Days 14 ≤ 90 0 (0.0) 84 3 (3.7) 81 0 (0.0) 79 0 (0.0) 74
Tracheo-bronchitis Overall 5 (4.8) 104 12 (12.2) 98 9 (9.0) 100 8 (8.2) 98 0.3022
Day 0 (baseline) 0 (0.0) 104 1 (1.0) 98 1 (1.0) 100 0 (0.0) 98
Days 0 to ≤7d 3 (2.9) 104 4 (4.1) 98 4 (4.0) 100 5 (5.1) 98
>Days 7 to ≤14 1 (1.0) 97 6 (6.7) 89 0 (0.0) 90 0 (0.0) 79
>Days 14 ≤ 90 1 (1.2) 84 2 (2.5) 81 5 (6.3) 79 2 (2.7) 74
Central venous catheter infection Overall 1 (1.2) 84 0 (0.0) 74 3 (4.1) 73 2 (2.6) 76 0.2863
Day 0 (baseline) 0 (0.0) 84 0 (0.0) 74 0 (0.0) 73 0 (0.0) 76
Days 0 to ≤7d 0 (0.0) 84 0 (0.0) 74 1 (1.4) 73 0 (0.0) 76
>Days 7 to ≤14 0 (0.0) 77 0 (0.0) 67 0 (0.0) 66 0 (0.0) 60
>Days 14 ≤ 90 1 (1.6) 64 0 (0.0) 61 2 (3.5) 57 2 (3.6) 55
Wound infection Overall 9 (11.0) 82 6 (8.5) 71 8 (10.7) 75 6 (7.8) 77 0.8960
Day 0 (baseline) 1 (1.2) 82 0 (0.0) 71 2 (2.7) 75 1 (1.3) 77
Days 0 to ≤7d 4 (4.9) 82 2 (2.8) 71 3 (4.0) 75 2 (2.6) 77
>Days 7 to ≤14 0 (0.0) 75 2 (3.1) 64 1 (1.5) 67 2 (3.3) 61
>Days 14 ≤ 90 5 (8.1) 62 2 (3.4) 58 4 (6.9) 58 2 (3.5) 57
Urinary tract infection Overall 4 (3.8) 104 5 (5.1) 98 7 (6.9) 101 9 (9.3) 97 0.4380
Day 0 (baseline) 0 (0.0) 104 0 (0.0) 98 1 (1.0) 101 0 (0.0) 97
Days 0 to ≤7d 0 (0.0) 104 1 (1.0) 98 2 (2.0) 101 1 (1.0) 97
>Days 7 to ≤14 2 (2.1) 97 0 (0.0) 89 2 (2.2) 91 3 (3.8) 78
>Days 14 ≤ 90 2 (2.4) 84 4 (4.9) 81 3 (3.8) 80 5 (6.8) 73
Note, percentages are based on the numbers of non-missing observations (n). ITT intention-to-treat, n (%) number (%) of patients, N number of patients in treatment
group, N’ number of patients with assessable data at start of the observation period, w/o adj without aluminum hydroxide adjuvant, with adj with aluminum hydroxide
adjuvant. aConfirmed by Clinical Endpoint Committee. bFisher-Freeman-Halton test, cbacteremia or pneumonia. dData from day 0 (baseline) are included in the row for
days 0 to ≤7. Therefore, the data for Overall include the rows for days 0 to ≤7, >days 7 to ≤14, and > days 14 to ≤90 rows, but not row for day 0 (baseline)
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[18] and in other studies with similar recombinant pro-
tein subunit vaccines, such as a Staphylococcus aureus
vaccine candidate [19]. The immune response was ob-
served irrespective of immunosuppressive status, gender,
and age. There was also some increase in OprF/I IgG in
placebo recipients, which is most likely linked to natural
exposure to P. aeruginosa. Safety parameters indicated a
good safety profile in all IC43 groups and IC43 was well-
tolerated up to doses of 200 μg.
This study found no difference in P. aeruginosa infec-
tion rates between patients vaccinated with IC43 and
placebo. However, the onset of infections was generally
early, often in the first week after admission to the ICU
and likely before the induction of an immune response by
vaccination. Over 70% of P. aeruginosa invasive infections
occurred before day 14, whereas the OprF/I-specific IgG
immune response only emerged between days 7 and 14. It
is thus likely that infections with an early onset might not
be preventable by the vaccine.
It should also be noted that the study was insuffi-
ciently powered for efficacy in terms of P. aeruginosa
infection rates, and the study methodology is likely to
have biased detection of infections up to and including
the day-14 visit (e.g. surveillance samples to test for
Fig. 4 Survival curve: time until death by treatment group. In the group randomized to 100 μg IC43 without adjuvant, there was statistically
significantly lower mortality versus placebo by day 28 (P = 0.0099, log-rank and Cox regression analysis) and significantly longer survival during
the study versus placebo (P = 0.0196, Cox regression analysis). w/o without aluminum hydroxide adjuvant
Table 7 SOFA score on days 0 (baseline), 7, and 14 (safety population)
SOFA score Parameter IC43 100 μg with adj
(N = 104)
IC43 100 μg w/o adj
(N = 98)




Day 0 n 104 98 101 98
(baseline) Mean (SD) 8.6 (3.5) 7.8 (3.5) 8.0 (3.2) 8.7 (3.7)
Median 8.0 8.0 8.0 9.0
Day 7 n 88 79 78 79
Mean (SD) 6.3 (4.1) 5.9 (4.1) 5.9 (3.6) 6.7 (4.5)
Median 6.0 5.0 6.0 5.0
Day 14 n 61 48 49 50
Mean (SD) 5.6 (3.8) 6.2 (4.1) 7.1 (4.5) 5.5 (4.7)
Median 5.0 5.5 6.0 4.0
n number of patients, SD standard deviation, SOFA sequential organ failure assessment, w/o adj without aluminum hydroxide adjuvant, with adj with aluminum
hydroxide adjuvant
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infection were taken at specified study time points
during the ICU stay only, mainly on days 7 and 14,
because the mean ICU stay was <28 days). It is possible
that the IC43 vaccine affects P. aeruginosa virulence
rather than clearance. This would not affect the infection
rate, but it would confer a potential benefit to patients
that would need to be measured by the use of additional
endpoints.
Mortality was assessed as a secondary endpoint.
Mortality in the group receiving 100 μg IC43 without
adjuvant, was significantly lower than in the placebo
group by day 28. Additionally, OprF/I-specific IgG anti-
body titer on day 14 was found to be a significant prog-
nostic factor for overall survival. Notably, the study was
not powered to detect a difference in mortality rates,
and mortality should be explored further in future trials.
The mechanism of action of IC43 is currently un-
known. Speculation on possible mechanisms centers on
effects mediated by the immunologically active outer
membrane proteins F and I expressed as antigens in the
recombinant vaccine. Little is known about the function
of OprI; however, the OprF protein is critical in the full
virulence of Pseudomonas as it mediates stimulation of
the quorum sensing network [20], which includes bind-
ing of human interferon-gamma [21]. It is not clear
whether antibodies to these two proteins will inhibit or
modify their amplifying actions, although previous stud-
ies showed that OprF/I vaccine-induced antibodies in-
hibits binding of P. aeruginosa to interferon-gamma,
suggesting an alternative mechanism [22].
We are aware that there are several confounders for
mortality rates reported in nosocomial infections, par-
ticularly in ICU studies. Indeed, there is strong correl-
ation between mortality and high SOFA scores on ICU
admission [23]. We did not notice major differences be-
tween the treatment groups in SOFA scores at baseline
or by day 14. The median SOFA score was lowest in the
placebo group, and further studies should be controlled
by severity of illness because the effect on outcomes is
reduced to intermediate ranges of severity. Thus, differ-
ences in SOFA score or severity of illness may have a
different impact on the attributable mortality.
Conclusions
In conclusion, our study has shown a significant immuno-
genic effect with IC43 vaccination in ventilated ICU pa-
tients. While it has been recognized that the development
of a vaccine against Pseudomonas infection has not been
successful for almost half a century [24], these data
provide rationale that vaccination against nosocomial
Pseudomonas infection may improve clinical outcome in
mechanically ventilated patients exposed to nosocomial
infections. In the absence of any difference in immune
response following administration of 100 μg IC43 without
adjuvant compared with 200 μg IC43 with adjuvant, the
100 μg dose without adjuvant was considered for further
testing of its possible benefit of improved survival in a
currently ongoing placebo-controlled phase II/III study.
Key messages
 This phase II study has shown that IC43 vaccination
produces a significant immunogenic effect in ICU
patients on ventilation.
 P. aeruginosa infection rates did not differ significantly
between groups.
 In the absence of any difference in immune response
following administration of the 100 μg dose of IC43
without adjuvant compared with the 200 μg dose
with adjuvant, the 100 μg dose without adjuvant was
considered for further testing of its possible benefit
of improved outcomes.
 There were no safety or mortality concerns.
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